DZ Bank’s Atossa Therapeutics ATOS Stock Holding History

DZ Bank’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1	Closed	-$26K	–	868
2018 Q1	$26K	Buy	+1	New	+$93	﹤0.01%	1045

Other funds holding ATOS

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DZ Bank's ATOS Position: Q2 2018 in Review

DZ Bank sold out of Atossa Therapeutics (ATOS) in Q2 2018, closing a stake of 1 share — an estimated $26K sold.

DZ Bank first reported a position in ATOS in Q1 2018 and held it in 1 quarter. The position peaked at $26K in Q1 2018. 14 funds tracked by Wall St. Rank hold ATOS as of Q2 2018.

DZ Bank reported no remaining Atossa Therapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 1 Atossa Therapeutics share in Q2 2018, an estimated $26K.
DZ Bank first reported a position in Atossa Therapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Atossa Therapeutics position peaked at $26K in Q1 2018.
14 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.